ReviewDiabetes research and clinical practice2014
SGLT2 inhibitors in the treatment of type 2 diabetes.
Review in Diabetes research and clinical practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02798744 (SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes.Journal of diabetes research · 2022Pooled it
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.Scientific reports · 2017 · on this mapPooled it
- Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.Internal medicine (Tokyo, Japan) · 2020Trial
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.Journal of diabetes investigation · 2019Trial
- Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Diabetes, obesity & metabolism · 2017Trial
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Cardiovascular diabetology · 2015Trial
- Trial
- SGLT2i-induced euglycemic diabetic ketoacidosis in a heart failure patient with acute myocardial infarction: a case report.Annals of medicine and surgery (2012) · 2025Article
- Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy.Scientific reports · 2025Article
- Click Reaction Inspired Enzyme Inhibitors in Diabetes Care: An Update in the Field of Chronic Metabolic Disorder.Current pharmaceutical design · 2025Review
- Review of nonpharmacological interventions for delaying the effects of cerebral neuropathy caused by diabetes.Frontiers in endocrinology · 2025Review
- SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International journal of molecular sciences · 2024Review
- Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.Current diabetes reviews · 2024Article
- Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients.Scientific reports · 2023Article
- Fasting and Post-Load Glucose and Non-Esterified Fatty Acids and Risk of Heart Failure and Its Subtypes in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Natural products targeting inflammation-related metabolic disorders: A comprehensive review.Heliyon · 2023Review
- Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors.African health sciences · 2023Article
- Risk of lower limb amputation in diabetic patients using SGLT2 inhibitorsTherapeutic advances in drug safety · 2023Article
- Effects of Empagliflozin on Intermittent Hypoxia-Induced TRAF3IP2-Dependent Human Aortic Smooth Muscle Cell Proliferation.Medical research archives · 2022Article
- The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study.Antioxidants (Basel, Switzerland) · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidney plays an important role in glucose homeostasis via its production, utilization, and, most importantly, reabsorption of glucose from glomerular filtrate which is largely mediated via the sodium glucose co-transporter 2 (SGLT2). Pharmacological inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 represent a novel class of drugs, which has recently become available for treatment of type 2 diabetes. This article summarizes the rationale for use of these agents and reviews available clinical data on their efficacy, safety, and risks/benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.